3 Top Diabetes Stocks to Buy Now
Diabetes is huge problem for Americans. Between 1990 and 2010, the number of U.S. residents with diabetes tripled, and the number of new cases annually doubled. Both prevalence and costs associated with diabetes are projected to increase by more than 50% by 2030.
But where there's a problem, there's also an opportunity. Healthcare companies continue to develop innovative new approaches to treating and managing diabetes. This innovation in turn creates value for investors.
At least 15 publicly traded companies have current products addressing diabetes either on the market or in development. A few of these stocks hold the potential to generate market-beating returns for investors. I think that Abbott Laboratories (NYSE: ABT), Becton, Dickinson and Company (NYSE: BDX), and Johnson & Johnson (NYSE: JNJ) will especially stand out over the next few years. Here's why these are three top diabetes stocks to buy now.
Source: Fool.com
Abbott Laboratories Stock
The stock is an absolute favorite of our community with 69 Buy predictions and no Sell predictions.
With a target price of 114 € there is a slightly positive potential of 16.16% for Abbott Laboratories compared to the current price of 98.14 €.
